Current Treatment Options in Gastroenterology

, Volume 6, Issue 6, pp 499–507 | Cite as

Current management of esophageal varices

  • Atif Zaman
Article

Opinion statement

Acute variceal hemorrhage is the most lethal complication of cirrhosis. The reported mortality rate from a first episode of variceal hemorrhage is 17% to 57%. Management of varices can be categorized into three phases: 1) prevention of initial bleeding, 2) management of acute bleeding, and 3) prevention of rebleeding. Modalities for treatment include pharmacologic, endoscopic, and shunt therapy. For the prevention of first variceal hemorrhage, cirrhotic patients should undergo endoscopy to identify patients with large varices. Priority for screening for varices should be given to patients with low platelet count, splenomegaly, and advanced cirrhosis. Once large varices are identified, patients should be started on β-blocker therapy, which reduces the risk of bleeding by 50%. If pharmacologic therapy is not tolerated or contraindicated, endoscopic band ligation should be performed, and surveillance of varices should be performed every 6 months thereafter. Shunt procedures are not indicated due to their higher rates of complications compared with medical therapy. For the management of acute variceal hemorrhage, patients should be started on prophylactic intravenous antibiotics and intravenous octreotide. Endoscopy should be performed to diagnose and treat variceal hemorrhage. Band ligation appears to be as effective as sclerotherapy, but with less complications. If hemostasis is not achieved, balloon tamponade can be used as a bridge to definitive therapy, which in this case would be a transjugular intrahepatic portosystemic shunt (TIPS). If TIPS is unavailable, a surgical shunt is indicated. Once an episode of acute bleeding has been controlled, variceal eradication is best accomplished with repeat band ligation every 10 to 14 days until varices are obliterated. Prevention of recurrent bleeding can be achieved with β-blocker therapy. The addition of isosorbide mononitrate further reduces recurrent bleeding. This combination pharmacologic therapy has been shown to be superior to sclerotherapy and may be superior to band ligation. However, side effects of combination pharmacologic therapy may limit its effectiveness. Band ligation is preferred to sclerotherapy when considering endoscopic therapy due to less complications and lower cost. Surgical shunts should be used for prevention of rebleeding in patients who do not tolerate or are noncompliant with medical therapy and who have relatively preserved liver function. TIPS should be reserved for patients who have poor liver function and who have failed medical therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dufour MC: Chronic liver disease and cirrhosis. In Digestive Diseases in the United States: Epidemiology and Impact. Edited by Everhart JE. Washington, DC: US Dept of Health and Human Services, NIH publication 94-1447; 1994:615–645.Google Scholar
  2. 2.
    Groszmann RJ, Bosch J, Grace ND, et al.: Hemodynamic events in a prospective randomized trial of propanolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990, 99:1401–1407.PubMedGoogle Scholar
  3. 3.
    Zaman A, Arnold RJ, Pettit K, et al.: Cost of treating an episode of variceal bleeding in a VA setting. Am J Gastroenterol 2000, 95:1323–1330.PubMedCrossRefGoogle Scholar
  4. 4.
    Boyer T: Natural history of portal hypertension. Clin Liver Dis 1997, 1:31–44.PubMedCrossRefGoogle Scholar
  5. 5.
    The Northern Italian Endoscopic Club for the Study and Treatment of Esophageal Varices: Prediction of first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988, 319:983–989.CrossRefGoogle Scholar
  6. 6.
    Chalasani N, Imperiale TF, Ismail A, et al.: Predictors of large varices in patients with cirrhosis. Am J Gastroenterol 1999, 94:3285–3291.PubMedCrossRefGoogle Scholar
  7. 7.
    Zaman A, Becker T, Lapidus J, et al.: Risk factors for the presence of varcies in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med 2001, 161:2564–2570.PubMedCrossRefGoogle Scholar
  8. 8.
    D’Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: a meta-analytic review. Hepatology 1995, 22:332–354.PubMedCrossRefGoogle Scholar
  9. 9.
    Andreani T, Poupon RE, Balkau B, et al.: Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propanolol, endoscopic sclerotherapy, and placebo. Hepatology 1990, 12:1412–1419.CrossRefGoogle Scholar
  10. 10.
    Angelico M, Carli L, Piat C, et al.: Effects of isosobide-5-mononitrate compared with propanolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997, 113:1632–1639.PubMedCrossRefGoogle Scholar
  11. 11.
    Garcia-Pagan JC, Villanueva C, Vila MC, et al.: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001, 121:908–914.PubMedCrossRefGoogle Scholar
  12. 12.
    Borroni G, Salerno F, Cazzaniga M, et al.: Nadolol is superior to isosorbide mononitrate for the prevention of first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002, 37:315–321.PubMedCrossRefGoogle Scholar
  13. 13.
    D’Amico G, Pagliaro L, Bosch J: Pharmacologic treatment of portal hypertension. An evidence based approach. Sem Liv Dis 1999, 19:475–506.CrossRefGoogle Scholar
  14. 14.
    The Veterans Affair Cooperative Variceal Sclerotherapy Group: Prophylactic sclerotherapy for esophageal varices in alcoholic liver disease: a randomized single-blinded, multicenter clinical trial. N Engl J Med 1991, 324:1779–1784.CrossRefGoogle Scholar
  15. 15.
    Imperiale TF, Chalasani N: A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001, 33:802–807. A well-done meta-analysis that reviews the evidence of the use of band ligation in the prevention of first variceal hemorrhage.PubMedCrossRefGoogle Scholar
  16. 16.
    Lui HF, Stanley AJ, Forrest EH, et al.: Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propanolol, and isosorbide mononitrate. Gastroenterology 2002, 123:735–744.PubMedCrossRefGoogle Scholar
  17. 17.
    Grace ND: Prevention of initial variceal hemorrhage. In Gastroenterology Clinics of North America: Complications of Portal Hypertension: Esophagogastric Varices and Ascites. Edited by Groszmann RJ, Grace ND. Philadelphia: WB Saunders; 1992:149–161.Google Scholar
  18. 18.
    Kravetz D, Bosch J, Arderiu M, et al.: Abnormalities in organ blood flow and its distribution during expiratory pressure ventilation. Hepatology 1989, 9:808–814.PubMedCrossRefGoogle Scholar
  19. 19.
    Bernard B, Nguyen KE, Opolon P, et al.: Antibiotic prophylaxis (ABP) for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding (GB): a meta-analysis. Hepatology 1999, 29:1655–1661.PubMedCrossRefGoogle Scholar
  20. 20.
    Ioannu GN, Doust J, Rockey D: Systematic review: terlipressin in acute oesophageal variceal hemorrhage. Aliment Pharmacol Ther 2003, 17:53–64.CrossRefGoogle Scholar
  21. 21.
    Corley DA, Cello JP, Adkisson W, et al.: Octreotide for acute esophageal variceal bleeding: meta-analysis. Gastroenterology 2001, 120:946–954. A good overview of the current role of the most commonly used pharamocologic agent in the management of acute variceal hemorrhage in the United States.PubMedCrossRefGoogle Scholar
  22. 22.
    Steigmann GV, Goff JS, Michaletz-Onody P, et al.: Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992, 326:1527–1532.CrossRefGoogle Scholar
  23. 23.
    Avgerinos A, Armonis A, Manolakpoulos S, et al.: Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding: a prospective randomized study. J Hepatol 1997, 26:1034–1041.PubMedCrossRefGoogle Scholar
  24. 24.
    Burroughs AK, Patch D: Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 1999, 19:457–473.PubMedGoogle Scholar
  25. 25.
    Jalan R, John TG, Redhead DN, et al.: A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol 1995, 90:1932–1937.PubMedGoogle Scholar
  26. 26.
    Smith JL, Graham DY: Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982, 82:968–973.PubMedGoogle Scholar
  27. 27.
    de Franchis R, Primignani M: Why do varices bleed? Gastroenterol Clin North Am 1992, 21:85–101.PubMedGoogle Scholar
  28. 28.
    Feu F, Garcia-Pagan JC, Bosch J, et al.: Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995, 346:1056–1059.PubMedCrossRefGoogle Scholar
  29. 29.
    Bernard B, Lebrec D, Mathurin P, et al.: Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997, 25:63–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Gournay J, Masliah C, Martin T, et al.: Isosorbide mononitrate and propanolol compared with propanolol alone for the prevention of variceal rebleeding. Hepatology 2000, 31:1239–1245.PubMedCrossRefGoogle Scholar
  31. 31.
    Villanueva C, Balanzo J, Novella MT, et al.: Nadolol plus isosorbide mononitratee compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996, 334:1624–1629.PubMedCrossRefGoogle Scholar
  32. 32.
    Villanueva C, Minana J, Ortiz J, et al.: Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001, 345:647–655.PubMedCrossRefGoogle Scholar
  33. 33.
    Lo GH, Chen WC, Chen MH, et al.: Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002, 123:728–734.PubMedCrossRefGoogle Scholar
  34. 34.
    Patch D, Sabin CA, Goulis J, et al.: A randomized, controlled trial medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002, 123:1013–1019.PubMedCrossRefGoogle Scholar
  35. 35.
    Bernard B, Lebrec D, Mathurin P, et al.: Propanolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis. J Hepatol 1997, 26:312–324.PubMedCrossRefGoogle Scholar
  36. 36.
    Laine L, Cook D: Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med 1995, 123:280–287.PubMedGoogle Scholar
  37. 37.
    Lo GH, Lai KH, Cheng JS, et al.: Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention variceal rebleeding: a prospective randomized trial. Hepatology 2000, 32:461–465.PubMedCrossRefGoogle Scholar
  38. 38.
    Spina GP, Henderson JM, Rikkers LF, et al.: Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. A metaanalysis of 4 randomized clinical trials. J Hepatol 1992, 16:338–345.PubMedCrossRefGoogle Scholar
  39. 39.
    Papatheodoridis GV, Goulis J, Leandro G, et al.: Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology 1999, 30:612–622.PubMedCrossRefGoogle Scholar
  40. 40.
    Rosemurgy AS, Serafini FM, Zwebel BR, et al.: Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portocaval shunt: extended follow-up of an expanded randomized prospective trial. J Gastrointest Surg 2000, 4:589–597. This major study suggests that surgical shunts may be a better alternative to TIPS for the prevention of recurrent variceal hemorrhage when medical therapy fails.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Atif Zaman
    • 1
  1. 1.Department of MedicineOregon Health & Science UniversityPortlandUSA

Personalised recommendations